In the Margins
In its annual report, Sequoia Fund manager Ruane, Cuniff & Goldfarb has vented about Valeant Pharmaceuticals' recent stock plunge, though it offers an optimistic outlook for the stock. The letter outlines how much Valeant’s relationship with affiliated pharmacy Philidor wreaked havoc for the fund company. Read the original story from Barron's.
Most Read
Invesco Funds expects to add two new independent and two new interested directors to its boardroom early in 2024, following a shareholder vote that also will ...
The boards overseeing TIAA's 88 and Nuveen Investments' 135 mutual funds plan to merge into a singe entity, nine years after TIAA acquired Nuveen for $6.25 ...
Mutual fund boardrooms are more diverse than ever, with the percentage of women and individuals representing a racial or ethnic minority group increasing annually—and at a ...
Independent mutual fund directors earned more in 2022 than they did in 2021, according to industry data obtained by Fund Board Views. The year-on-year increase—a median of ...